ASCO18: Tecentriq scores again in lung cancer, but Keytruda looms in background

Adding Roche's Tecentriq to a chemotherapy regimen helped reduce the risk of disease progression or death for patients with an advanced type of lung cancer, according to data presented Saturday at the American Society of Clinical Oncology's annual meeting.